MedTrace Logo

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

NCT01825928 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-07-13

No results posted yet for this study

Summary

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. paliperidone are Second generation antipsychotics，and have effects of blocking dopamine2(D2) and 5-hydroxytryptamine 2A(5-HT) receptors neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among methamphetamine addicts.

Conditions

  • Methamphetamine Dependence

Interventions

DRUG

Paliperidone

Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days

DRUG

placebo

placebo group,3mg/pill,3mg/day forced titration method,last 84 days

Sponsors & Collaborators

  • Wei Hao

    lead OTHER

Principal Investigators

  • Wei Hao, MD., Ph.D. · Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-04-30
Completion
2014-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01825928 on ClinicalTrials.gov